Source comparison
Best PT-141 Dosage for Female Arousal: Clinical vs Research Comparison
0.5mg Partial. Some effect, often subtherapeutic 15–20% 10% Initial tolerance test; useful for assessing side effects before committing to full dose Too low for consistent efficacy. Use only as a starting point 1.0mg Moderate. Noticeable but weaker than clinic
This comparison does not assign a generated winner or score.
- 0.5mg
- Partial. Some effect, often subtherapeutic
- 15–20%
- 10%
- Initial tolerance test; useful for assessing side effects before committing to full dose
- Too low for consistent efficacy. Use only as a starting point
- 1.0mg
- Moderate. Noticeable but weaker than clinical dose
- 25–30%
- 15%
- Mid-range option for patients with high nausea sensitivity
- Works for some, but most will need 1.75mg for full benefit
- 1.75mg
- Optimal. Receptor saturation achieved, maximum arousal response
- 40% (attenuates with repeat use)
- 20%
- FDA-approved clinical dose; supported by Phase 3 data
- Gold standard. Balance of efficacy and tolerability
- 2.0mg+
- No additional arousal benefit; ceiling effect confirmed
- 50%+
- Off-label; no efficacy data supports doses above 1.75mg
- Wastes product and amplifies side effects without improving outcomes